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Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an essen-
tial regulator of T-cell responses, and its absence precipitates le-
thal T-cell hyperactivity. However, whether CTLA-4 acts simply to
veto the activation of certain clones or plays a more nuanced role
in shaping the quality of T-cell responses is not clear. Here we
report that T cells in CTLA-4–deficient mice show spontaneous T-
follicular helper (TFH) differentiation in vivo, and this is accompa-
nied by the appearance of large germinal centers (GCs). Remark-
ably, short-term blockade with anti–CTLA-4 antibody in wild-type
mice is sufficient to elicit TFH generation and GC development. The
latter occurs in a CD28-dependent manner, consistent with the
known role of CTLA-4 in regulating the CD28 pathway. CTLA-4
can act by down-regulating CD80 and CD86 on antigen presenting
cells (APCs), thereby altering the level of CD28 engagement. To
mimic reduced CD28 ligation, we used mice heterozygous for
CD28, revealing that the magnitude of CD28 engagement is tightly
linked to the propensity for TFH differentiation. In contrast, other
parameters of T-cell activation, including CD62L down-regulation
and Ki67 expression, were relatively insensitive to altered CD28
level. Altered TFH generation as a result of graded reduction in
CD28 was associated with decreased numbers of GC B cells and
a reduction in overall GC size. These data support a model in which
CTLA-4 control of immunity goes beyond vetoing T-cell priming
and encompasses the regulation of TFH differentiation by graded
control of CD28 engagement.
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Control of the magnitude and nature of adaptive immuneresponses is critical for health. The cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4)/CD28 axis has long been known
to control the magnitude of T-cell responses, however whether it
also influences their nature has not been clear. Early studies
suggested that CD28 may be particularly important for Th2
differentiation (1, 2), although others identified roles for CD28
in both Th1 and Th2 responses (3, 4). It is known that CD28 is an
absolute requirement for the differentiation of follicular helper
T cells (TFHs) that support germinal center (GC) formation (5,
6). However, these studies generally make use of CD28-deficient
T cells, and therefore, results may reflect a failure of the cells to
properly activate, proliferate, or survive, particularly given the
known contribution of CD28 to these processes.
A key outstanding question is whether CD28 costimulation in
vivo is more complex than a binary checkpoint for T-cell priming.
It is clear that expression of costimulatory ligands on antigen
presenting cells (APCs) fluctuates in response to environmental
stimuli, being up-regulated by inflammatory cytokines and TLR
agonists and down-regulated by Treg-expressed CTLA-4 (7–11).
Thus, variable levels of costimulatory ligands will be available for
CD28 binding depending on the microenvironmental context.
However, whether this simply alters the number of T cells that
achieve the required threshold to commit to a response or whether
it influences the nature of the response is not clear. Effective im-
mune homeostasis appears to be reliant on maintaining an appro-
priate level of CD28 engagement. For example, basal expression of
CD28 ligands, in particular dendritic cell-expressed CD86 (12), is
critical to Treg homeostasis (13, 14), whereas excessive CD28 en-
gagement in the absence of CTLA-4 results in lethal autoimmunity
(15, 16). Nonetheless, distinguishing whether these effects are
simply quantitative is not straightforward. Thus, although levels of
CD28 ligands are clearly variable in vivo, our understanding of the
impact of altering the level of CD28 engagement is still incomplete.
To explore the impact of varying levels of CD28 ligation, we
have used the CTLA-4–deficient mouse as a model of exces-
sive CD28 stimulation. In these mice, we observed a striking
skewing toward TFH differentiation, with induction of IL-21 and
spontaneous formation of GCs. In a complementary approach,
we used CD28 heterozygosity to decrease T cell CD28 expres-
sion: This revealed that the level of CD28 engagement is tightly
coupled to the level of inducible T-cell costimulator (ICOS) in-
duction, TFH generation, and GC formation, whereas other
parameters of T-cell activation were less affected. Finally, we
demonstrate that induction of the microRNA cluster miR17-92,
recently linked with TFH differentiation (17, 18), varies pro-
portionally with APC costimulatory ligand expression and is
modulated by CTLA-4 deficiency or blockade. Collectively, these
data suggest that the CTLA-4/CD28 axis provides quantitative
and qualitative control of T-cell help for humoral immunity.
Results
CTLA-4 Deficiency or Blockade Augments TFH Numbers. Mice lacking
CTLA-4 exhibit a lethal CD28-dependent lymphoproliferative
syndrome with evidence of skewing to Th2 (19). However, the
impact of CTLA-4 deficiency on TFH differentiation has not
previously been examined. We therefore analyzed spleen (Fig. 1)
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and lymph node (Fig. S1) CD4 T cells for expression of a panel
of TFH markers. CD4 T cells from CTLA-4–deficient mice
expressed elevated levels of the TFH markers PD-1 and CXCR5
(Fig. 1A). IL-21, the archetypal cytokine associated with TFH
differentiation, was up-regulated at the mRNA (Fig. S1C) and
protein (Fig. 1B) level in conventional T cells (Tconv) from
CTLA-4–deficient mice compared with age-matched wild-type
controls. Consistent with augmented TFH differentiation, B cells
with a GC phenotype (Fas+GL-7+) were readily detectable in
the lymph nodes (LNs) and spleens of CTLA-4–deficient mice
(Fig. 1C and Fig. S1), and immunohistological analysis revealed
spontaneous GC formation (Fig. 1D). The systemic immune
dysregulation associated with CTLA-4 deficiency makes it hard
to establish whether features observed in these animals reflect
a direct effect of CTLA-4 deficiency or a secondary effect of
disease. Indeed, the T-cell compartment in CTLA-4–deficient
mice shows evidence of extensive activation (Fig. S2). We
therefore performed short-term CTLA-4 blockade studies in
wild-type mice. Remarkably, short-term blockade of CTLA-4
was sufficient to induce the appearance of TFH cells (Fig. 2A),
GC B cells (Fig. 2B), and immunohistologically evident GCs
(Fig. 2C) in the spleen. Similar effects were noted in the LNs
(Fig. S3 A and B). There was marked Bcl6 up-regulation in CD4
T cells from anti–CTLA-4 Ab-injected mice (Fig. 2D). GC for-
mation could be detected as early as 3 d following anti–CTLA-4
Ab injection (Fig. S4A), and injection of control Ab did not in-
duce GC formation (Fig. S4B). Importantly, GC formation was
CD28-dependent, as anti–CTLA-4 Ab did not elicit sponta-
neous GC formation in CD28-deficient mice (Fig. S4C). To
assess whether GC formation following CTLA-4 blockade was
associated with autoantibody production, we first used serum
from CTLA-4–deficient mice to confirm a suitable target
autoantigen. Serum from CTLA-4–deficient, but not wild-type
mice, stained stomach sections from Rag2−/− mice (Fig. S5A),
consistent with the previous demonstration that deficiency of
CTLA-4 in Treg triggers the production of antiparietal cell
antibodies (Abs) and autoimmune gastritis (9). Interestingly,
serum from mice treated with anti–CTLA-4 Ab also showed
reactivity to Rag2−/− stomach sections, whereas serum from
control-treated mice did not (Fig. S5B). In addition, anti-dsDNA
Abs were detected in mice treated with anti–CTLA-4 Ab (Fig.
S5C). Collectively, these data indicate that the CTLA-4 pathway
controls TFH development in a CD28-dependent manner and
that persistent CTLA-4–mediated regulation is required to pre-
vent the spontaneous emergence of TFHs, GCs, and autoantibodies.
Quantitative Effect of CD28 on TFH Development. Because the phe-
notype of CTLA-4−/− mice is likely due to excessive CD28
Fig. 1. CTLA-4 deficiency elicits spontaneous T-cell help for GCs. (A) Rep-
resentative staining and collated data showing the proportion of TFH
(CXCR5+PD-1+) in splenic CD4 T cells from 15- to 19-d CTLA-4−/− mice or
CTLA-4+/− littermate controls. (B) Spleen cell suspensions from 15- to 18-d
CTLA-4−/− or CTLA-4+/+ mice were restimulated and stained for CD4 and in-
tracellular Foxp3 and IL-21. Plots show representative IL-21 staining and col-
lated data. n = 5–7, ***P < 0.001. (C) Spleen cells from 15- to 19-d CTLA-4−/−
mice or CTLA-4+/− littermate controls were stained for the GC B-cell markers
FAS and GL-7. Plots are gated on CD19+ cells, and representative staining and
collated data are shown. (D) Frozen spleen sections from 17-d CTLA-4−/− mice
or CTLA-4+/− littermate controls were stained for CD4 or PNA (blue) and IgD
(brown). F, follicle; GC, germinal center; T, t zone.
Fig. 2. CTLA-4 blockade triggers TFH differentiation and GC formation.
BALB/c mice were treated with 500 μg of anti–CTLA-4 Ab (or control hamster
IgG) every 2 d, and spleens were harvested on day 5 or 11. Representative
FACS plots and pooled data for TFH frequency in gated CD4+ cells (A) and GC
B-cell frequency in gated CD19+ cells (B). ***P < 0.001, *P < 0.05; ns, not
significant. (C) Immunohistological staining of frozen spleen sections showing
CD4 (blue) and IgD (brown) (Top) or PNA (blue) and IgD (brown) (Bottom).
Images are from one experiment (n = 3) and are representative of three in-
dependent experiments with similar results. (D) CD4 T cells frommice treated for
11 d with anti–CTLA-4 Abs or control Abs were stained for expression of Bcl6,
Gata3, and Tbet. Plots are gated on CD4+Foxp3– cells. Collated data depict fold
increase in transcription factor mean fluorescence intensity (MFI) in CTLA-4 Ab-
treated mice relative to control Ab-treated mice. n = 4, ***P < 0.001.
Wang et al. PNAS | January 13, 2015 | vol. 112 | no. 2 | 525
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
engagement (20, 21), we hypothesized that the GC response
should also be influenced by directly affecting levels of CD28 on
T cells. To probe whether changing the amount of CD28 en-
gagement on Tconv altered their ability to support GC forma-
tion, we performed adoptive transfer experiments comparing
CD28+/+, CD28+/−, and CD28−/− T cells. In this way, we were
able to alter the level of CD28 available for ligation on the T
cells, as CD28 expression was markedly lower on CD28+/− T cells
compared with CD28+/+ T cells (Fig. S6A). Importantly, het-
erozygosity, rather than total deficiency, offers a better model of
raising or lowering the level of CD28 engagement that could
result from Treg-mediated ligand down-regulation on APCs. To
ensure the absence of background GCs at the start of the experi-
ment, CD28−/− mice were used as recipients; thus, in this system,
the ability to support GC formation is restricted to the adoptively
transferred T cells. DO11 T cells that were CD28+/+, CD28+/−, or
CD28−/− were transferred, and recipient mice were immunized in-
traperitoneally with alum-precipitated hapten-conjugated ovalbumin
(NP-OVA).
DO11 T cells from CD28+/− mice showed a markedly reduced
propensity to acquire a TFH phenotype (based on coexpression of
CXCR5 and PD1) (Fig. 3A) compared with their CD28+/+
counterparts, and this correlated with a decreased number of B
cells bearing a GC B-cell phenotype (Fig. 3B). We noted that
average GC size was also decreased in mice receiving CD28+/− T
cells (Fig. 3C) and that Ab titres were lower than in recipients of
CD28+/+ T cells (Fig. S7A). A major pathway implicated in the
generation of GC responses is the ICOS pathway, the absence of
which is associated with a defect in GC formation (22–25). T
cells from CD28+/− mice also showed a graded decrease in ICOS
expression, with ICOS levels being intermediate compared with
CD28+/+ and CD28−/− T cells (Fig. 3D). Interestingly, not all
activation markers were similarly affected by CD28 heterozy-
gosity: CD62L down-regulation in CD28+/− T cells was similar to
that seen in wild-type T cells, and Ki67 levels were comparable,
indicating equivalent proliferation (Fig. 3 E and F). Analysis of
Cell Trace profiles at early time points confirmed the similar
proliferative response of CD28+/+ and CD28+/− T cells (Fig.
S7B). It should be noted that the percentage and absolute
number of DO11 T cells recovered was broadly equivalent for
CD28+/+ and CD28+/− cells but very low for CD28−/− cells,
consistent with poor T-cell survival in the complete absence of
CD28 (Fig. 3G). Taken together, these data reveal that T-cell
activation in the context of reduced CD28 engagement has
a marked effect on TFH differentiation, while minimally altering
CD62L down-regulation, proliferation, and survival.
CD86 Is the Dominant Ligand for TFH Development. Because the
acquisition of a TFH phenotype, and support for GC formation,
was clearly modulated by CD28 signaling, we sought to identify
the CD28 ligand driving this process. Adoptive transfer experi-
ments were performed using CD28+/+ DO11 T cells, and
blocking Abs were injected against CD80, CD86, or both. The
capacity of the CD80 and CD86 Ab to block their respective
ligands was verified in vitro (Fig. S8A). Blockade of CD80 had
only a modest effect on the frequency of TFH cells (Fig. 4A), and
this was associated with a marked but incomplete reduction in
GC B cells (Fig. 4B). In contrast, in the presence of CD86 Ab,
the percentage of TFH cells was severely reduced—virtually to
the same extent as when CD86 and CD80 were both blocked
(Fig. 4A). The frequency of GC B cells was similarly impaired
with CD86 blockade, to a comparable extent as with the simul-
taneous blockade of both ligands (Fig. 4B). The pattern of ICOS
expression showed the same trend (Fig. 4C), whereas the data
suggested a higher degree of redundancy between ligands for IL-
21 production (Fig. 4D). Effects of ligand blockade on pro-
duction of IFNγ and IL-17 and on CD62L expression are shown
in Fig. S8B. Collectively, these experiments revealed that CD86
was the dominant CD28 ligand for generating the TFH cells that
support GC development.
Graded Control of the microRNA-17–92 Cluster by CD28. The miR-
17–92 cluster has recently been shown to promote TFH genera-
tion (17, 18) and is induced in mouse T cells stimulated with anti-
CD3 and anti-CD28 (26). We found that naïve T cells stimulated
with anti-CD3 and anti-CD28 up-regulated higher levels of miR-
17, an indicator miR for expression of this cluster, than those
stimulated with anti-CD3 alone and that lack of CD28 stimula-
tion could not be substituted by provision of IL-2 (Fig. 5A). To
assess the impact of CD28 engagement using natural ligands
rather than Abs, we activated naïve T cells in the presence of
purified splenic B cells from CD80CD86+/+, CD80CD86+/−, or
CD80CD86−/− mice, which express graded levels of CD80 and
CD86 (Fig. S6B). This revealed a clear dose-dependent effect of
CD80 and CD86 on miR-17 expression (Fig. 5B). Additional
experiments revealed that deficiency or blockade of CTLA-4 led
to increased T-cell miR-17 expression (Fig. S9). These data
suggest that by altering expression levels of costimulatory
ligands, CTLA-4 has the capacity to influence key controllers of
the TFH differentiation program.
Discussion
Multiple studies demonstrate the association between the CTLA-
4/CD28 axis and autoimmunity (27–29). More recently, a link
between TFH differentiation and autoimmunity has emerged (30,
Fig. 3. Quantitative effect of CD28 on TFH and GC B-cell development.
DO11 CD28+/+, DO11 CD28+/−, or DO11 CD28−/− T cells (2 × 105) were injected
into CD28−/− mice that were immunized i.p. with 200 μg of NP-OVA/alum 24
h later. At day 8, spleens were harvested for analysis. (A) Percentage of TFH
(CXCR5+PD-1+) within gated CD4+DO11+ T cells. (B) Percentage of GC B
cells (Fas+GL-7+) within the CD19+ gate. (C) Average GC size based on staining
of spleen sections for PNA and IgD. Each point represents the mean of >60 GCs
scored in an individual spleen. (D) ICOS, (E) CD62L, and (F) Ki67 expression on
CD4+DO11+ T cells. (G) Percentage and absolute number of DO11 T cells. Data
for A–G are compiled from two experiments (n = 4–6).
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31). Accordingly, overproduction of TFH in mice with a roquin
mutation is associated with severe autoimmune disease (32, 33),
and elevations in T cells with a TFH phenotype have been noted in
systemic lupus erythematosus (34), myasthenia gravis (35, 36), and
rheumatoid arthritis (37) (refs. 30, 31 and the references therein).
Our data show that control of immunity via the CTLA-4/CD28
axis and control of TFH generation are fundamentally linked.
TFH cells provide a key link between T-cell activation and the
ability to generate high-affinity class-switched Abs via GCs. The
association between TFH and autoimmunity has sparked an in-
creasing interest in understanding how TFH generation and function
is regulated. It has been reported that a population of Qa1-
restricted CD8 T cells expressing CXCR5 can regulate TFH numbers
in a manner dependent on perforin expression (38). More recently,
a subset of regulatory T cells termed TFR (T-follicular regulatory)
has been identified that enter the GC and have the capacity to limit
TFH and GC B-cell numbers (39–41). Thus, the magnitude of TFH
and GC responses is likely controlled by specialized Treg.
A major portion of CTLA-4 function can be attributed to its role
in Treg (9, 42) and CTLA-4 expression, along with IL-2 repression,
is the minimal requirement to confer Treg-like suppressive activity
(43). One mechanism of action of CTLA-4 is the down-regulation
of costimulatory ligands on APCs (7–10), which can occur via
a process of transendocytosis (11). This results in decreased avail-
ability of ligands for CD28-mediated costimulation of T cells.
Accordingly, Treg-expressed CTLA-4 can directly control CD28
signaling in Tconv by restricting CD28 ligand availability. In-
triguingly, Tconv can also use CTLA-4 to mediate transendocytosis
(11), and we (44) and others (45) have shown that Tconv-expressed
CTLA-4 can elicit regulation in a cell-extrinsic manner. This
suggests a common mechanism of action for CTLA-4 regardless
of the cell type on which it is expressed. Thus, CTLA-4, on both
Treg and Tconv, can down-regulate costimulatory ligands and
thereby decrease T-cell CD28 stimulation. Although one major
impact of CTLA-4 function is clearly to prevent self-reactive
T-cell activation, additional functions may include its impact on
T-cell differentiation and B-cell responses as indicated here.
The mechanism used by TFR to regulate the GC response is
not yet clear. Notably, TFRs express CTLA-4 at high levels (39),
suggesting they are well placed to use the CTLA-4 pathway to
elicit suppression. Indeed, TFRs were clearly detectable in GC
induced by anti–CTLA-4 Ab treatment (Fig. S10), consistent
with the idea that despite their correct positioning TFRs are
unable to regulate GCs in the absence of CTLA-4. Furthermore,
in one study, TFRs were reported to express low levels of CD25
(39), suggesting a decreased capacity to use IL-2 sequestration
(46) as a suppressive mechanism. Indeed, consuming local IL-2
may be of limited value in regulating the TFH responses, as IL-2
itself inhibits TFH differentiation (47–50).
It has been shown that TFRs limit the outgrowth of non-
antigen-specific B cells in the GC (39), thereby regulating GC
size. Indeed, the deletion of B cells that are unable to elicit T-cell
help is a key selection step within the GC that permits affinity
maturation of the humoral response. The importance of such
deletion is exemplified by the lymphoproliferative disease that
affects mice in which Fas-mediated apoptosis is blocked in GC B
cells (51). The simplest explanation for the capacity of TFR to
control GC size is that they limit TFH number and thereby re-
strict the ability of T cells to rescue GC B cells from death.
Because TFH homeostasis is tightly linked to the availability of
costimulatory ligands on B cells (52, 53), it is easy to envisage
how TFR could use the CTLA-4 pathway to control TFH by down-
regulating costimulatory ligand expression on B cells.
TFHs are endowed with the capacity to solicit CD86 expression
on B cells via production of IL-21 (54) or IL-4 (55). Thus, high-
affinity B cells that competitively capture antigen from follicular
dendritic cells, and productively engage with TFHs in the light zone
of GCs, may be rewarded with cytokines that up-regulate their
CD86 expression. This allows them to offer CD28 engagement to
the T cells providing help, likely augmenting IL-21 production and
beginning a feedback loop that will ensure entry of the clone
into the long-lived plasma cell or memory B-cell pool.
That a complete block in CD28 signaling abrogates the GC
response has been known for some time. We previously reported
(6) that this reflected a requirement for CD28 to up-regulate
CXCR5 on T cells, the chemokine receptor that allows them to
respond to CXCL13 expressed in the B-cell follicle. Accordingly,
in mice where CD28 signaling was blocked by transgenic ex-
pression of CTLA-4–Ig, T cells failed to up-regulate CXCR5;
however, CXCR5 up-regulation, follicular migration, and GC
formation could be restored if CD80/86 blockade was bypassed
by injection of agonistic anti-CD28 (6). Thus, CD28 plays a
critical role in resetting the T-cell chemokine receptor balance
that permits T-cell localization to the B-cell follicles. Here we
move beyond the simple presence or absence of costimulation and
instead explore how the strength of CD28 signaling alters T-cell
fate. We demonstrate that sensing of costimulatory ligands in vivo
is analog and not digital—that is, it is not all or nothing but reflects
the overall level of CD28 engagement. Commitment to a TFH
phenotype appears to require a higher level of CD28 engagement
than commitment to proliferation or CD62L down-regulation. This
Fig. 4. CD86 is the dominant ligand for TFH and GC development. CD28
−/−
mice were injected i.v. with DO11 WT T cells (0.2 × 106). One day later, mice
were injected i.p. with 200 μg of NP-OVA/alum or PBS (no imm) and received
two doses of anti-CD80 Ab, anti-CD86 Ab, or both i.p., as indicated (day 1
and day 5). At day 8, spleen cells were analyzed by flow cytometry. (A)
Percentage of TFH (CXCR5+PD-1+) within gated CD4+DO11+ T cells. (B)
Percentage of GC B cells (Fas+GL-7+) in gated CD19+ cells. (C) MFI ICOS
expression within gated CD4+DO11+ T cells. (D) Percentage IL-21+ cells
within CD4+DO11+Foxp3– cells after restimulation and intracellular stain-
ing. Data are compiled from 2 experiments (n = 3–5). ***P < 0.001, **P <
0.01, *P < 0.05; NS, not significant.
Fig. 5. Graded control of the microRNA-17–92 cluster by CD28. (A) BALB/c
CD4+CD25− T cells were stimulated for 1, 2, or 3 d (D1, D2, D3) with anti-CD3
alone or in the presence of anti-CD28 or 20 ng/mL of IL-2. mRNA was
extracted, and levels of miR-17 expression were assessed. Graph shows fold
change relative to naive CD4+CD25− T cells. Graph shows one experiment
and is representative of three independent experiments with similar results.
(B) BALB/c CD4+CD25− T cells were cultured for 3 d in the presence of anti-
CD3, with costimulation being provided by splenic CD19+ B cells isolated
from CD80CD86+/+, CD80CD86+/−, or CD80CD86−/− mice. T cells were re-
isolated at day 3, and miR-17 mRNA levels were assessed. Graph shows
collated data from three independent experiments. Statistical analysis was
performed by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001.
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may reflect the fact that such commitment also licenses the B-cell
response and therefore serves as an additional checkpoint in the
adaptive immune response. Indeed, our data suggest that the level
of CD28 signaling directly couples the magnitude of the T-helper
response to the magnitude of the B-cell response.
In addition to CD28-mediated induction of CXCR5, ICOS-
derived signals are required to enhance T-cell motility to facili-
tate entry to the B-cell follicle (56). Accordingly, the failure of
ICOS-deficient T cells to enter B-cell follicles cannot be over-
come by transgenic expression of CXCR5 (56). The division of
labor between CD28 and ICOS in control of T-cell help for
B cells has been a topic of intense debate. We and others
previously suggested a hierarchy of costimulatory interactions in
which CD28 operates upstream of ICOS (57, 58). This is con-
sistent with CD28 being expressed on naïve T cells while ICOS is
induced following T-cell activation (59). Indeed, it was noted that
restricting ICOS function to downstream of CD28 was key to
maintaining two-signal control of T-cell responses (60). We now
extend this concept and suggest that CD28 and ICOS function are
inherently coupled. Our data demonstrate that the strength of
CD28 signaling in vivo translates directly into the level of ICOS
surface expression induced on the T cell. This provides an elegant
mechanism linking CD28 engagement to the ICOS-dependent ac-
tivation of PI3K known to be critical for the generation of TFHs (61,
62). Thus, neither CD28 nor ICOS alone is sufficient to induce the
TFH program, consistent with microarray data obtained following
independent engagement of these receptors (63). Rather, our data
suggest that CD28 and ICOS function together to confer the TFH
phenotype. The long-range linkage disequilibrium reported at the
CD28 and ICOS loci (64) may lock together variants that function
coordinately to couple T- and B-cell function.
Although the CD28-dependent up-regulation of ICOS is likely
to be a key step in driving TFH generation, it is not the sole
mediator of the response. Accordingly, CD28−/− mice over-
expressing ICOS as a consequence of roquin mutation do not
form spontaneous GCs (although GCs can be induced by im-
munization) (60). Thus, overstimulation of CD28, as a consequence
of CTLA-4 deficiency or blockade (Figs. 1 and 2), induces a distinct
phenotype from overexpression of ICOS. Other mechanisms by
which CD28 may promote TFH generation include regulation of the
microRNA cluster 17–92, as shown here. Recent data revealed that
expression of the miR-17–92 cluster is critical for the differentiation
and function of TFH (17, 18). Indeed, overexpression of miR-17–92
promotes TFH generation (17), and transgenic expression of miR-
17–92 in T cells can drive spontaneous TFH differentiation and GC
formation, similar to our findings with CTLA-4 deficiency and
blockade (18). The functionally relevant targets of the miR-17–92
cluster are still unclear, but the mechanism of action is likely to
include direct and indirect repression of genes that antagonize TFH
differentiation. Control of genes that regulate the PI3K pathway
(e.g., the PI3K antagonist PTEN and the AKT phosphatase
PHLPP2) may be particularly important (17, 18), consistent with
the well-recognized role of PI3K in the GC response (61, 62).
The relative contribution of CD86 and CD80 to T-cell–dependent
Ab responses is still unclear. The dominant role for CD86 identified
here is consistent with the demonstration that CD86−/− mice show
a more profound defect in GC formation than CD80−/− mice (65).
Given the sequential interaction of T cells with dendritic cells
(DCs) and B cells during humoral responses, this could reflect
distinct cell type-specific or kinetic expression patterns between
ligands. Of note, studies have documented the importance of
either CD86 (52) or CD80 (53) on B cells for TFH generation
and GC responses. It is possible that the nature and context of
the antigenic challenge dictate the relative requirement for
CD80 versus CD86, consistent with the capacity of strong adju-
vants to restore the GC response in CD86−/− mice (65).
Collectively our data demonstrate that fine-tuning the degree of
CD28 engagement—for example, by CTLA-4–dependent down-
regulation of costimulatory ligands on DCs or GC B cells—results
in tailored modulation of the TFH response. Thus, T-cell–dependent
humoral immunity is tightly controlled by the CTLA-4 pathway.
Materials and Methods
Mice. BALB/c and DO11.10 mice were from The Jackson Laboratory and
CD28−/− mice from Taconic Laboratories. BALB/c CTLA-4−/− mice were kindly
provided by A. Sharpe (Harvard, Boston, MA). CD80CD86−/−mice were from the
Mutant Mouse Regional Resource Center. Mice were housed in individually
vented cages at University College London or within the University of Birming-
ham Biological Services Unit. Experiments were performed in accordance with
the relevant Home Office project and personal licenses following institutional
ethical approval (University of Birmingham and University College London).
Flow Cytometry. Cells were stained with Ab against CD4 (RM4-5; BD Bio-
sciences), ICOS (7E.17G9), PD-1 (RMP1-30; Biolegend), CXCR5 (SPRCL5), CD19
(ID3; BDBiosciences), FAS (Jo2; BD Biosciences), GL7 (GL7; BD Biosciences), CD3
(17A2), Foxp3 (FJK-16s), IL-21 (mhalx21), DO11.10 TCR (KJ1-26), CD62L (MEL-
14), Ki67 (B56; BD Biosciences), CD28 (37.51; BD Biosciences), Bcl6 (K112-91),
Gata3 (L50-823; BD Biosciences), and Tbet (4B10, Biolegend). All Abs were
purchased from eBioscience unless otherwise stated. For IL-21 measurement,
cells were stimulated with phorbol myristate acetate (PMA) and ionomycin
for 5 h in the presence of brefeldin A. For IL-21, Foxp3, and Ki67 staining,
cells were fixed and permeabilized (eBioscience).
RT-PCR. Cells were purified by sorting (MoFlo, Dako Cytomation), and RNA was
isolated using RNAzol B (Biogenesis), reverse transcribed and interrogated for
IL-21 (TaqMan, Applied Biosystems) using the Stratagene MX3000P real-time
PCR detection system. Gene expression was normalized to β-actin levels.
Immunohistochemistry and Confocal Microscopy. Acetone-fixed frozen 5-μm
spleen sections were stained with sheep anti-IgD (Abcam) and rat anti-CD4
(BD Biosciences) or biotinylated peanut agglutinin (PNA; Vector Labs). Sec-
ond step reagents were HRP-conjugated donkey anti-sheep IgG (Binding
Site), biotinylated rabbit anti-rat Igs, followed by Streptavidin–ABComplex–
alkaline phosphate (Vector Labs). Staining was visualized using FastBlue and
DAB (3,3′-diaminobenzidine; Sigma-Aldrich). We incubated 5-μm cryostat
sections from rag2−/− stomach with serum samples from CTLA-4–deficient,
wild-type, or Ab-treated mice, as indicated. Bound Ab was detected with
anti-mouse IgG-555, and sections were counterstained with DAPI. Images
were captured by confocal microscopy (Zeiss LSM 510 Meta).
In Vivo Experiments. BALB/c mice 9–10 wk old were injected with anti–CTLA-4
blocking Ab (4F10) or hamster IgG i.p. every 2 d. For adoptive transfer
experiments, DO11 T cells (2-7 × 105) from DO11 WT, DO11 CD28+/−, or DO11
CD28−/− mice were injected i.v. into CD28−/− recipients. Where indicated,
cells were labeled with Cell Trace Violet. One day later, recipients were
immunized i.p. with 200 μg of NP-OVA/alum. Anti-CD80 (clone 16–10A1),
anti-CD86 (clone GL-1) blocking Ab, or both (100 μg each Ab per injection)
were injected twice i.p. where indicated (first dose immediately before an-
tigen administration, second dose 4 d postimmunization). Control Ab-treated
mice received 100 μg of rat IgG and 100 μg of hamster IgG. All injections were
carried out in the morning, in the absence of anesthesia and analgesia, and
mice were returned immediately to the home cage following the pro-
cedure. The welfare of experimental animals was monitored regularly
(typically immediately postprocedure, then at least every 2–3 d). No
adverse events were noted during these experiments.
miRNA Analysis. CD4+CD25– T cells and CD19+ B cells were purified from LNs
and spleens of BALB/c mice, respectively, by magnetic separation (Miltenyi
Biotec). T cells (5 × 104 cells per well) were activated with 2 μg/mL of plate-
bound anti-CD3 Ab alone or in combination with 5 μg/mL of anti-CD28 or
20 ng/mL of IL-2. In some experiments, T cells activated with anti-CD3 in the
presence of B cells (2:1 B:T ratio). Three days later, B cells were removed by
magnetic cell separation, and T cells were snap-frozen for RNA extraction.
For ex vivo miR-17 analysis, splenic CD4 T cells were isolated from age-
matched WT, CTLA-4+/−, CTLA-4−/−, or anti–CTLA-4 Ab-treated mice. Total
RNA was extracted using a mirVana miRNA Isolation Kit (Ambion, Life
Technologies) and converted to cDNA with a TaqMan MicroRNA Reverse
Transcription Kit. The miRNA expression levels of mouse miR-17 were
established by real-time PCR using Taqman primers (Taqman, Life Tech-
nologies) and a 7500 Fast RT-PCR system (Applied Biosystems, Life Tech-
nologies). Expression was normalized against RNA from freshly isolated
CD4+CD25– T cells and the sno202 housekeeping gene, with the ΔΔ cyclic
threshold method used to calculate relative fold change.
Statistics. Statistical analysis was performed using Graphpad Prism version 5,
and P values were calculated by two-tailed, unpaired t test for the means
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with a 95% confidence interval. Analysis of more than two samples was
performed by one-way ANOVA.
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